Recharacterization of RSL3 reveals that the selenoproteome is a druggable target in colorectal cancer.
DeAngelo SL, Zhao L, Dziechciarz S, Shin M, Solanki S, Balia A, El-Derany MO, Castillo C, Qin Y, Das NK, Bell HN, Paulo JA, Zhang Y, Rossiter NJ, McCulla EC, He J, Talukder I, Ng BW, Schafer ZT, Neamati N, Mancias JD, Koutmos M, Shah YM.
DeAngelo SL, et al. Among authors: zhao l.
bioRxiv [Preprint]. 2024 Aug 27:2024.03.29.587381. doi: 10.1101/2024.03.29.587381.
bioRxiv. 2024.
PMID: 38617233
Free PMC article.
Preprint.